High antimicrobial resistance in urinary tract infections in male outpatients in routine laboratory data, Germany, 2015 to 2020

Background Evidence on the distribution of bacteria and therapy recommendations in male outpatients with urinary tract infections (UTI) remains insufficient. Aim We aimed to report frequency distributions and antimicrobial resistance (AMR) of bacteria causing UTI in men and to identify risk factors for resistance of Escherichia coli against trimethoprim (TMP) and ciprofloxacin (CIP). Methods We conducted a retrospective observational study using routinely collected midstream urine specimens from 102,736 adult male outpatients sent from 6,749 outpatient practices to nine collaborating laboratories from all major regions in Germany between 2015 and 2020. Resistance in E. coli was predicted using logistic regression. Results The three most frequent bacteria were E. coli (38.4%), Enterococcus faecalis (16.5%) and Proteus mirabilis (9.3%). Resistance of E. coli against amoxicillin (45.7%), TMP (26.6%) and CIP (19.8%) was common. Multiple drug resistance was high (22.9%). Resistance against fosfomycin (0.9%) and nitrofurantoin (1.9%) was low. Resistance of En. faecalis against CIP was high (29.3%). Isolates of P. mirabilis revealed high resistance against TMP (41.3%) and CIP (16.6%). The CIP and TMP resistance was significantly higher among bacteria derived from recurrent UTI (p < 0.05). Age ≥ 90 years, recurrent UTI and regions East and South were independently associated with AMR of E. coli against TMP and CIP (p < 0.05). Conclusion The most frequent UTI-causing pathogens showed high resistance against TMP and CIP, empirical therapy is therefore likely to fail. Apart from intrinsically resistant pathogens, susceptibility to fosfomycin and nitrofurantoin remains sufficient. Therefore, they remain an additional option for empirical treatment of uncomplicated UTI in men.

[1]  Long-hua Hu,et al.  Impact of inappropriate empirical antibiotic treatment on clinical outcomes of urinary tract infections caused by Escherichia coli: a retrospective cohort study. , 2021, Journal of global antimicrobial resistance.

[2]  J. Gaston,et al.  Polymicrobial Interactions in the Urinary Tract: Is the Enemy of My Enemy My Friend? , 2021, Infection and immunity.

[3]  Akke Vellinga,et al.  Treatment of uncomplicated UTI in males: a systematic review of the literature , 2020, BJGP open.

[4]  J. Justo,et al.  Prediction of Sulfamethoxazole/Trimethoprim Resistance in Community-Onset Urinary Tract Infections. , 2020, Journal of global antimicrobial resistance.

[5]  N. Frimodt-Møller,et al.  Treatment duration of pivmecillinam in men, non-pregnant and pregnant women for community-acquired urinary tract infections caused by Escherichia coli: a retrospective Danish cohort study. , 2019, The Journal of antimicrobial chemotherapy.

[6]  V. Sakka,et al.  Oral fosfomycin for the treatment of chronic bacterial prostatitis , 2019, The Journal of antimicrobial chemotherapy.

[7]  T. Tängdén,et al.  Retrospective evaluation of nitrofurantoin and pivmecillinam for the treatment of lower urinary tract infections in men , 2019, PloS one.

[8]  T. Eckmanns,et al.  Antibiotic-Resistant E. coli in Uncomplicated Community-Acquired Urinary Tract Infection. , 2018, Deutsches Arzteblatt international.

[9]  A. Novelli,et al.  Pharmacological properties of oral antibiotics for the treatment of uncomplicated urinary tract infections , 2017, Journal of chemotherapy.

[10]  B. Trautner,et al.  Urinary Tract Infection , 2012, Annals of Internal Medicine.

[11]  A. Lewis,et al.  Gram-Positive Uropathogens, Polymicrobial Urinary Tract Infection, and the Emerging Microbiota of the Urinary Tract , 2016, Microbiology spectrum.

[12]  A. G. Ellis,et al.  Fosfomycin for Treatment of Prostatitis: New Tricks for Old Dogs. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  D. Skaare,et al.  Antibiotic resistance patterns of bacteria causing urinary tract infections in the elderly living in nursing homes versus the elderly living at home: an observational study , 2015, BMC Geriatrics.

[14]  K. Mergenhagen,et al.  Effectiveness and safety of nitrofurantoin in outpatient male veterans , 2015, Therapeutic advances in urology.

[15]  J. Penders,et al.  The Importance of Gender-Stratified Antibiotic Resistance Surveillance of Unselected Uropathogens: A Dutch Nationwide Extramural Surveillance Study , 2013, PloS one.

[16]  E. Hummers-Pradier,et al.  Resistance profiles of urinary tract infections in general practice - an observational study , 2012, BMC Urology.

[17]  R. Colgan,et al.  Diagnosis and treatment of acute uncomplicated cystitis. , 2011, American family physician.

[18]  J. Gussekloo,et al.  Predictive factors of urinary tract infections among the oldest old in the general population. a population-based prospective follow-up study , 2011, BMC medicine.

[19]  Betsy Foxman,et al.  The epidemiology of urinary tract infection , 2010, Nature Reviews Urology.

[20]  M. P. van der Linden,et al.  Regional differences in serotype distribution, pneumococcal vaccine coverage, and antimicrobial resistance of invasive pneumococcal disease among German federal states. , 2010, International journal of medical microbiology : IJMM.

[21]  A. Marchese,et al.  The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. , 2009, International journal of antimicrobial agents.

[22]  J. Car Urinary tract infections in women: diagnosis and management in primary care , 2006, BMJ : British Medical Journal.

[23]  T. Griebling Urologic diseases in america project: trends in resource use for urinary tract infections in men. , 2005, The Journal of urology.

[24]  Peter C Austin,et al.  A brief note on overlapping confidence intervals. , 2002, Journal of vascular surgery.

[25]  F. Selvaggi,et al.  EAU Guidelines for the Management of Urinary and Male Genital Tract Infections1 , 2001, European Urology.

[26]  J. Sobel,et al.  Urinary tract infection: self-reported incidence and associated costs. , 2000, Annals of epidemiology.

[27]  J. Hamilton-miller,et al.  The mysterious 'urethral syndrome'. , 1991, BMJ.